InMed Pharmaceuticals Inc (NASDAQ:INM) does about 7.04M shares in volume on a normal day but saw 2959459 shares change hands in the recent trading day. The company now has a market cap of 1.32M USD. Its current market price is $0.40, marking a decrease of -3.35% compared to the previous close of $0.41. The 52 week high reached by this stock is $2.08 whilst the lowest price level in 52 weeks is $0.12.
InMed Pharmaceuticals Inc (INM) has a 20-day trading average at $0.2109 and the current price is -80.88% off the 52-week high compared with 229.49% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2403 and its 200-day simple moving average is $0.3202. If we look at the stock’s price movements over the week, volatility stands at 36.88%, which decreases to 18.73% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 72.01 to suggest the stock is overbought.
The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 98.0% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Hold the stock.
The current price level is 93.55%, 67.70%, and 24.12% away from its SMA20, SMA50, and SMA200 respectively, with the INM price moving below the 50-day SMA on current market day. InMed Pharmaceuticals Inc (INM) stock is up 183.26% over the week and 41.53% over the past month. Its price is -4.40% year-to-date and -51.93% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. In addition, estimates put the company’s current quarterly revenue at an average of $1.79M.
To reach the target analysts have set, the stock logically needs to grow 98.0 percent from here.
The company has a return on investment of -51.36% and return on equity of -51.73%. The beta has a value of 0.64. Price to book ratio is 0.23 and price to sales ratio is 0.24.
